Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
137.42
+3.17 (2.36%)
Jul 30 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 135.02 - 138.30
52 week 93.74 - 170.45
Open 135.02
Vol / Avg. 276,809.00/320,951.00
Mkt cap 45.84B
P/E     -
Div/yield     -
EPS -2.80
Shares 333.57M
Beta 0.31
Inst. own 85%
Jul 31, 2014
Q2 2014 Valeant Pharmaceuticals International, Inc. Earnings Release - 9:30AM EDT - Add to calendar
Jul 31, 2014
Q2 2014 Valeant Pharmaceuticals International Inc Earnings Call - 8:00AM EDT - Add to calendar
Jun 17, 2014
Valeant Pharmaceuticals International Inc Conference Call to Correct Recent Misrepresentations
Jun 2, 2014
Valeant Pharmaceuticals International, Inc. Conference Call to Discuss Revised Offer for Allergan
May 28, 2014
Valeant Pharmaceuticals International, Inc. at Sanford C Bernstein Strategic Decisions Conference
May 28, 2014
Valeant Pharmaceuticals International, Inc. Investor Meeting to Discuss the Merger Proposal with Allergan Conference Call
May 20, 2014
Valeant Pharmaceuticals International, Inc. Annual Shareholder Meeting - Webcast
May 12, 2014
Allergan Conference Call to discuss the Rejection of Unsolicited Proposal from Valeant Pharmaceuticals International, Inc
May 8, 2014
Q1 2014 Valeant Pharmaceuticals International, Inc. Earnings Release
May 8, 2014
Q1 2014 Valeant Pharmaceuticals International, Inc. Earnings Conference Call
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -1.08% -14.97%
Operating margin 13.94% -8.22%
EBITD margin - 51.28%
Return on average assets -0.29% -3.76%
Return on average equity -1.78% -19.60%
Employees 17,200 -
CDP Score - -

Address

2150 ST. ELZEAR BLVD. WEST
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)

Website links

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.